Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing
American Journal of Clinical Pathology · 2024
DOI: 10.1093/ajcp/aqad169 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2024. Verfasst von Carlos A Munoz-Zuluaga und 6 weiteren Autor:innen. Beteiligte Einrichtung: Divisions of Cytopathology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, US. Hauptthemen laut MEDLINE: Thyroid Nodule, Thyroid Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objectives
Afirma has recently introduced its Xpression Atlas (XA) as an adjunct to its Genomic Sequencing Classifier (GSC) for risk stratification of cytologically indeterminate thyroid nodules. We evaluated the performance of Afirma XA and associated pathologic findings for Afirma GSC suspicious nodules.
Methods
Intradepartmental records of thyroid fine-needle aspirations (FNAs) from January 2021 to December 2022 were identified and reviewed for patient and nodule characteristics, FNA findings, molecular test results, and final surgical pathology, if available.
Results
Material for Afirma GSC testing was collected in 624 thyroid FNAs, and 148 (24%) were classified as cytologically indeterminate. Afirma GSC testing was successful in 132 (89%) of those cases, of which 35 (27%) were Afirma GSC suspicious. Afirma XA testing was positive in 11 cases (11/35 [31%]). Eight (73%) patients underwent surgery that revealed 7 patients with papillary thyroid carcinoma and 1 patient with noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) (risk of malignancy: 100% [8/8]). Among the 24 patients with negative Afirma XA results, 19 (79%) underwent surgery, revealing 5 patients with malignancy and 3 patients with NIFTP (risk of malignancy: 42% [8/19]). Overall, the risk of malignancy for Afirma GSC suspicious nodules was 59% (16/27).
Conclusions
Afirma XA improved risk stratification of thyroid disease with a high risk of malignancy in Afirma GSC suspicious nodules. A negative Afirma XA result, however, should not be used as a rule-out test.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Divisions of Cytopathology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, US.
- Divisions of Head and Neck Pathology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, US.
- Divisions of Molecular and Genomic Pathology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, US.
- Department of Pathology, The Ohio State University College of Medicine, Columbus, OH, US.
ORCID-Profile: Hamza N Gokozan
Zitieren
APA
Munoz-Zuluaga, C. A., Heymann, J. J., Solomon, J. P., Patel, A., Siddiqui, M. T., Scognamiglio, T., & Gokozan, H. N. (2024). Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqad169
Vancouver
Munoz-Zuluaga CA, Heymann JJ, Solomon JP, Patel A, Siddiqui MT, Scognamiglio T, et al. Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing. American Journal of Clinical Pathology. 2024. doi:10.1093/ajcp/aqad169
BibTeX
@article{MunozZuluaga2024,
author = {Munoz-Zuluaga, Carlos A and Heymann, Jonas J and Solomon, James P and Patel, Ami and Siddiqui, Momin T and Scognamiglio, Theresa and Gokozan, Hamza N},
title = {Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing},
journal = {American Journal of Clinical Pathology},
year = {2024},
doi = {10.1093/ajcp/aqad169}
}
EUVIMED